PolyPid Ltd. Ordinary Shares - PYPD STOCK NEWS

PolyPid Ltd. (PYPD) announced FDA approval for a single pivotal Phase 3 study of D-PLEX100 for preventing surgical site infections (SSIs) in colorectal surgery. This decision is based on the adequate results expected from the SHIELD I trial, which has already enrolled over 200 patients. The trial aims to include a total of 616 to 900 participants across multiple centers and is set to deliver top-line results by year-end 2021. This breakthrough designation could expedite development and reduce costs significantly, addressing a major healthcare issue costing up to $10 billion annually.

PolyPid Ltd. (Nasdaq: PYPD) announced significant recruitment progress in its Phase 3 SHIELD I trial of D-PLEX100, with nearly 200 patients enrolled, a doubled recruitment rate in the last three weeks. The manufacturing facility is fully equipped to meet the first 30 months of commercial demand for D-PLEX100. Financial results reveal a net loss of $8.7 million for Q1 2021, an increase from $5.9 million in Q1 2020. Cash reserves stand at $61.4 million, expected to sustain operations into 2022. Top-line results for SHIELD I are anticipated by year-end 2021.

PolyPid Ltd. (Nasdaq: PYPD) announced it will release its first quarter 2021 financial results on May 12, 2021, before the U.S. market opens. A conference call is scheduled for 8:30 AM ET to discuss the results and business updates. PolyPid is focused on enhancing surgical outcomes through its patented PLEX technology, which offers controlled drug delivery over extended periods. Their lead candidate, D-PLEX100, is currently undergoing Phase 3 trials targeting surgical site infections.

PolyPid Ltd. (Nasdaq: PYPD) announced its participation in two major healthcare conferences. The company will present at the Raymond James 42nd Annual Institutional Investors Conference on March 3, 2021, at 8:20 AM Eastern Time, and at the Barclays Global Healthcare Conference on March 9, 2021, at 7:30 AM Eastern Time. Both events will feature one-on-one investor meetings, and webcasts will be available for replay. PolyPid focuses on improving surgical outcomes with its extended-release therapeutics.

PolyPid Ltd. (Nasdaq: PYPD) announced the enrollment of the 100th patient in its Phase 3 SHIELD I clinical trial, focused on preventing surgical site infections (SSIs) following abdominal surgery. The trial aims to enroll between 616 to 900 patients across over 60 centers globally. Top-line results are anticipated by the end of 2021. PolyPid's lead product, D-PLEX100, utilizes proprietary technology for prolonged antibiotic release, receiving Breakthrough Therapy Designation from the FDA for specific surgical procedures.

PolyPid Ltd. (Nasdaq: PYPD) reports significant updates as of February 10, 2021. The company has enrolled 100 patients in the Phase 3 trials of D-PLEX100 aimed at preventing surgical site infections (SSIs) in abdominal surgeries. D-PLEX100 has received Breakthrough Therapy Designation from the FDA specifically for elective colorectal surgery. PolyPid also announced positive preclinical data for its new OncoPLEX cancer therapy and maintains a robust financial position with $66.6 million in cash as of December 31, 2020, following a successful IPO. Top-line results from SHIELD I are anticipated by year-end 2021.

PolyPid Ltd. (Nasdaq: PYPD) announced it will report its Q4 and full year 2020 financial results on February 10, 2021, before U.S. markets open. The company will hold a conference call at 8:30 AM ET to discuss the results and operational updates. PolyPid focuses on improving surgical outcomes with its proprietary PLEX technology that allows for targeted, prolonged-release therapeutics. Its lead product, D-PLEX100, is in Phase 3 trials for preventing surgical site infections.

PolyPid Ltd. (Nasdaq: PYPD) announced positive preclinical data for its OncoPLEX cancer therapy, demonstrating improved overall survival and reduced tumor recurrence in a syngeneic mouse model for colon carcinoma. A single local treatment of OncoPLEX showed a 25% tumor recurrence rate versus 75% in the systemic treatment group, and 75% overall survival compared to 50%. Systemic toxicity was also significantly lower. The company plans to complete an IND package with further preclinical studies and initiate a Phase 1 clinical trial in 2022, showcasing the potential of its novel PLEX technology for cancer treatment.

PolyPid Ltd. (PYPD) announced the enrollment of the first patient in its Phase 3 clinical trial, SHIELD II, for its D-PLEX100 product candidate aimed at preventing surgical site infections (SSIs) post-abdominal surgery. This follows the FDA's Breakthrough Therapy Designation for D-PLEX100. The trial aims to involve up to 1,400 patients across 60 centers. Top-line results from the ongoing SHIELD I trial are expected in the second half of 2021, which, along with SHIELD II, will support the company's New Drug Application submission.